AZN Related Analyst Comments
-
Jefferies Lifts PT on Pharmaceuticals Stocks (ABBV) (NVS) (SNY) (PFE)
-
Dupilumab Could End of Being 'Blockbuster' Asthma Drug - Analyst (SNY) (REGN)
-
Amarin's (AMRN) Vascepa Tracking Well 3-Months In; Investors Eye Tier 2 Designation
-
Leerink Swann Maintains an 'Outperform' on Teva Pharma (TEVA); Review with Patent Specialist
-
Amarin (AMRN) NCE Status Could Happen by September 14 and Takeover Could Follow - MKM
-
Nomura Securities Reiterates a 'Reduce' on AstraZeneca (AZN); Overpayment Risk in Deal with Bristol Myers (BMY)
-
Jefferies on Pharmaceuticals: Global Pharmaceuticals Q2'12 Earnings Preview; Where is it Safe to Hide?
-
Barclays on AstraZeneca (AZN): Acquisition of AMLN Makes Strategic Sense but High Price Tag
-
Jefferies Discusses Array BioPharma (ARRY) After Detailed Selumetinib Ph2 Data in NSCLC
-
Cantor Fitzgerald Maintains a 'Buy' on Warner Chilcott (WCRX); Let's Make It Official
-
Analysts Expecting Higher Bids for Amylin (AMLN)
-
Canaccord Genuity Reiterates a 'Buy' on Impax Labs (IPXL); Raising Estimates on Deal Announcement; Sentiment Starting to Shift
-
Needham & Company on Impax Labs (IPXL): Not a Strategic Game-Change but Zomig Offsets SG&A Ramp and Provides Short-Term EPS Boost
-
Needham & Company Maintains a 'Hold' on Targacept (TRGT); Sidelined Until TC5214 Phase 3 Story in Depression is Fully Resolved
-
Jefferies on Abbott (ABT) Split: Pharma Unit Could Be Worth $29/Share, Medical Unit $32/Share
-
Needham & Company Maintains a 'Buy' on Targacept (TRGT); Expect Continued Positive Results from AZN Collaboration
-
Barclays on U.S. Diagnostics: FDA Issues draft guidance on companion diagnostics; Positive read for QGEN
-
Barclays on U.S. Retail Hardlines: Wag.com - Initial Take/Pricing Study on New Pet Supply E-commerce Site
-
Eli Lilly (LLY) Might Be M&A Target if Things Don't Shape Up
-
Global Pharmaceuticals: Global Therapeutic Conference 2011: Focus on Real-World Medicine
-
UPDATE - Needham & Company Upgraded Targacept (TRGT) to Strong Buy; Valuation Attractive after Distraction of AstraZeneca TC-5619 Option Decision
-
Jefferies Cuts Price Target on POZEN Inc. (POZN) by 28.5%, Major Patent Risk
-
Barclays on Healthcare Services: Weekly Flu Clues Review
-
Barclays Reiterates an 'Overweight' on Array BioPharma (ARRY); Reports FY2Q11, Data for MEK inhibitors in 2011
-
Leerink Swann Raises Target on Savient (SVNT) to $22; Highlights Takeover Potential Following Krystexxa Approval
-
Brean Murray Maintains a 'Buy' on Pozen, Inc. (POZN); Raises PT on Belief in Vimovo's Approval
-
Wedbush Maintains an 'Outperform' on Nektar Therapeutics (NKTR), Recent Marketing Trip Focused on Upcoming Ovarian Cancer Data
-
Morgan Joseph Reiterates a 'Buy' on Nektar Technology (NKTR); Sees Substantial Added Value From AstraZeneca Deal
-
Natixis Bleichroeder Lifts Price Target on Targacept (TRGT) to $7.50
-
Citi Analysts Call 2009 Global Equity Outlook 'Battling The Bear' - Issue Global Preferred List
-
Merrill Lynch added AstraZeneca plc (AZN) to its Least Preferred List
-
Citi Maintains 'Buy' on POZEN (POZN), Increases Price Target
-
Shire plc (SHPGY) Higher On AstraZeneca Takeover Rumors
-
Goldman Sachs removed AstraZeneca plc (AZN) from their Conviction Buy list
-
Gene Marcial's BusinessWeek's Picks Of The Weeks (GENR, PBR, CWST)
-
Rodman & Renshaw Comments on the "Aftershock" of MEDI/AZN Deal
-
Jim Cramer mentions NUVO, CATG, and NSTK
-
Citigroup Raises its Price Target on AZN
-
Analyst Note Revisited After AGIX/AZN Deal
-
UBS Cuts its Price Target on OSIP
Back to AZN Stock Lookup
